'Sun Pharma Shares' - 124 News Result(s)

  • SPARC Q4 Net Loss Widens To Rs 9.6 Crore
    SPARC Q4 Net Loss Widens To Rs 9.6 Crore

    Sun Pharma Advanced Research Company (SPARC), the pharma research and drug discovery arm of Sun Pharma, on Friday reported a slight increase in its stand-alone net loss at Rs 9.58 crore for the quarter to March 2016.

  • Sun Pharma Shares Hit As Taro Stops Keveyis Sales
    Sun Pharma Shares Hit As Taro Stops Keveyis Sales

    Sun Pharmaceuticals Industries' shares fell nearly 4 per cent on Tuesday after its New York Stock Exchange-listed subsidiary Taro Pharmaceutical stopped commercial sales of Keveyis, a drug used in treatment of periodic paralysis.

  • Sun Pharma Shares Up 2% On USFDA Nod For BromSite
    Sun Pharma Shares Up 2% On USFDA Nod For BromSite

    Sun Pharma stock price rose by nearly 2 per cent on Monday as it received approval from the US health regulator USFDA for its non-steroid drug BromSite used to treat inflammation and prevent pain in patients undergoing cataract surgery.

  • Sun Pharma Rises as Company Buys 14 Brands From Novartis
    Sun Pharma Rises as Company Buys 14 Brands From Novartis

    Shares of Sun Pharma rose by nearly 3 per cent today as the drug major forayed into the Japanese prescription market by acquiring 14 brands from Swiss drug firm Novartis for $293 million (over Rs 1,940 crore).

  • Sensex in Narrow Range Amid Cautious Trade
    Sensex in Narrow Range Amid Cautious Trade

    Indian shares were little changed on Tuesday amid caution ahead of the expiry of monthly derivative contracts later this week and a speech from Federal Reserve Chair Janet Yellen later in the day.

  • Pharma Stocks Reel Under Heat of Government Action
    Pharma Stocks Reel Under Heat of Government Action

    Pharma stocks were under strong selling pressure for second consecutive day, weighed down by a weekend order from the government banning over 300 drugs.

  • Sensex Falls 286 Points on Selloff in Metal Shares
    Sensex Falls 286 Points on Selloff in Metal Shares

    UPL, Sun TV Network, MRPL, Jidal Steel, NALCO, Torrent Pharma, JSW Steel and Glenmark were among the losers from the mid-cap space, down 3-4.6 per cent each.

  • TCS, Sun Pharma, 7 Others Lose Rs 78,511 Crore in Market Value
    TCS, Sun Pharma, 7 Others Lose Rs 78,511 Crore in Market Value

    Overall weakness in the equity market dragged down the combined market valuation of nine of the top ten most valued Indian companies by a whopping Rs 78,511.56 crore for the week ended January 8.

  • Sensex Edges Higher in Listless Trading Session
    Sensex Edges Higher in Listless Trading Session

    Some amount of buying was visible in realty, pharma, media and infrastructure shares while mild selling pressure was seen in select metal, IT and banking stocks.

  • Buy Rel Power, Sun TV; Sell Sun Pharma: Sarvendra Srivastava
    Buy Rel Power, Sun TV; Sell Sun Pharma: Sarvendra Srivastava

    Sarvendra Srivastava, CMT-head technical research at Phisense.com, says the Nifty has managed to close above the important 7,850 levels in the holiday-shortened week (December 21-24) despite weak volumes.

  • Sun Pharma Shares Rebound on Value-Buying
    Sun Pharma Shares Rebound on Value-Buying

    Shares of Sun Pharma rebounded on Tuesday after slumping 4.5 per cent on Monday. Shares of India's biggest pharma company gained as much as 2 per cent today on value-buying at lower levels.

  • Sun Pharma Slumps After US Issues New Reprimand to India Drug Industry
    Sun Pharma Slumps After US Issues New Reprimand to India Drug Industry

    Shares in India's largest drugmaker, Sun Pharmaceutical Industries Ltd, skidded more than 7 percent on Monday after U.S. regulators warned of standards violations at a key plant in the latest blow to India's generic drug industry.

  • Sensex Ends 217 Points Higher, Led by Gains in Banking Shares
    Sensex Ends 217 Points Higher, Led by Gains in Banking Shares

    The Sensex rose 217 points to close at 25,736 and the 50-share Nifty advanced 72 points to settle at 7,834 on the back of gains in banking, metal and IT shares.

  • Sun Pharmaceutical Industries Shares Sink on FDA Warning Letter
    Sun Pharmaceutical Industries Shares Sink on FDA Warning Letter

    The US Food and Drug Administration's (US FDA) warning letter to Sun Pharma indicates the agency is dissatisfied with the remedial measures the company has implemented since last September, when the FDA first notified the company of its concerns after an inspection.

  • Sun Pharma Gains on Sale of US Manufacturing Unit
    Sun Pharma Gains on Sale of US Manufacturing Unit

    However, the company did not disclose the financial details of the transaction. Sun Pharma said impact of this development on its financials will be negligible.

  • Sun Pharma Inks Pact to Develop Nervous System Drugs
    Sun Pharma Inks Pact to Develop Nervous System Drugs

    Scientists at Weizmann Institute have developed a recombinant enzyme currently undergoing animal studies for indications of brain stroke and glioblastoma.

  • Sun Pharma Extends Rally on Anti-Cancer Drug Approval
    Sun Pharma Extends Rally on Anti-Cancer Drug Approval

    Sun Pharma shares have underperformed the broader Nifty in the last three months as the company is struggling with issues at its Halol manufacturing facility, Ranbaxy integration as well as pricing pressure in the United States, the company's largest market.

  • Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug
    Sun Pharma Gets US Regulator's Nod for Cancer Treatment Drug

    Drug major Sun Pharmaceutical Industries on Friday said one of its subsidiaries has received approval of the US Food and Drug Administration (FDA) to manufacture and market generic version of Novartis' Gleevec, used in treatment of cancer, in America.

  • Sun Pharma Surges Over 6% on New Drug Approval
    Sun Pharma Surges Over 6% on New Drug Approval

    Sun Pharma is expected to commercially launch the product on February 1, 2016. "Under the terms of a settlement agreement with Novartis, the Sun Pharma subsidiary is permitted to launch its version of generic Gleevec in the United States on February 1, 2016," the company said.

  • Sun Pharma Surges After Taro Drops Wind Energy Plans
    Sun Pharma Surges After Taro Drops Wind Energy Plans

    Shares of Sun Pharma surged as much as 4.5 per cent to Rs 739 after its US-listed subsidiary Taro decided not to proceed with investment in wind energy projects.

 
 

Advertisement

Advertisement

Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2016. All rights reserved.